Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17964096 | 0.85 | GAA (0.52) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL17194942 | 0.85 | MAPT (0.39) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL2255510 | 0.84 | SOAT1 (0.39) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL19677667 | 0.84 | EGLN1 (0.38) | EGLN1ALDH1A1TSHR | |
| SCHEMBL2204826 | 0.83 | ALDH1A1 (0.43) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL16808974 | 0.82 | ALDH1A1 (0.36) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL10644070 | 0.82 | ALDH1A1 (0.36) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL17188463 | 0.81 | CES2 (0.41) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL6129631 | 0.79 | EGLN1 (0.54) | EGLN1ALDH1A1CYP2D6SMN1; SMN2GAA | |
| SCHEMBL13499946 | 0.78 | FAAH (0.46) | ALDH1A1NPSR1GLO1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2802567-B1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-03-01 | — | — | EP | disclosed |
| US-8901124-B2 | Pyridazine amide compounds useful as SYK inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2014-12-02 | — | — | US | disclosed |
| EP-2802567-A1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013104573-A1 | PYRIDAZINE AMIDE COMPOUNDS AND THEIR USE AS SYK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-07-18 | — | — | WO | disclosed |
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | HOFFMAN-LA ROCHE INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-20040142930-A1 | Cyclic compounds | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2004-07-22 | — | — | US | disclosed |
| US-20030229089-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. (JP) | 2003-12-11 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178478-A1 | PYRIDAZINE AMIDE COMPOUNDS | SYK, BTK, IRAK2 | EGLN1 3516/4885ALDH1A1 3705/4885CYP2D6 2663/4885 |
| US-20030229089-A1 | Cyclic compounds | PDE3B, PDE5A, PDE9A | EGLN1 902/4885ALDH1A1 1341/4885CYP2D6 1129/4885 |
| US-20040142930-A1 | Cyclic compounds | PDE3B, PDE4A, PDE5A | EGLN1 788/4885ALDH1A1 1392/4885CYP2D6 1066/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | EGLN1 1903/4885ALDH1A1 1483/4885CYP2D6 975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.